Sharer stands down in Amgen transition; Danish biotech announces deep staffing cuts; UK readies £250M life sciences initiative;

Biotech News

 @FierceBiotech: Vitamin D boosts TB shot as cancer therapy. More | Follow @FierceBiotech

 @RyanMFierce: Pfizer brings Lipitor brand to mobile app stores. Report | Follow @RyanMFierce

 @JohnCFierce: So Globe's verastem coverage says best-case scenario is start trials in a year, products available in four. A three-year cancer stem cell program? Ha. | Follow @JohnCFierce

> It's the end of an era at Amgen ($AMGN) as Kevin Sharer steps down as CEO and hands the reins of the big biotech to Bob Bradway. Story

> Denmark's Veloxis is circling the wagons around its lead therapy to prevent organ rejection. The biotech says it plans to cut anywhere from 25 to 30 staffers from its 60-person employee roster. Release

> U.K. science minister David Willets is expected to announce £250 million in fresh support for the country's life sciences industry today. Story

> Bloomberg makes the case that GlaxoSmithKline's ($GSK) propensity for buying biotechs it collaborates with points to possible M&A moves in the future. Report

> Blueprint Medicines says that Fidelity Biosciences has joined the lineup of venture groups involved in its $40 M A round announced earlier. Stephen Knight, the managing partner at Fidelity, has joined the Blueprint board. Release

Pharma News

 @FiercePharma: Another German drugmaker in takeover talks: Riemser may pick shortlist by next week--BloombergStory | Follow @FiercePharma

> New Teva chief slashes sales forecast by $1B. News

> EU antitrust officials probe parallel trade. Article

> Securities watchdogs reportedly probe Shanghai Pharma deals. Item

> FDA panel draws blood in Xarelto's bid for new use. Report

Medical Device News

 @FierceMedDev: HeartWare gained expanded European approval for its HVAD implant. Trials continue in the U.S., however. Story | Follow @FierceMedDev

 @MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> Orrin Hatch pulls device tax repeal amendment from user fee bill. Report

> Once spectrum is approved, wireless patient monitors still face obstacles. Article

> Alere recalls thousands of cardiac diagnostic tests. More

> House Republicans push for tax-repeal vote. Item

Pharma Manufacturing News

 @EricPFierce: FDA to Crescendo: We told you so. Marshals seize steroid gel from California firm that was selling unapproved drug. Report | Follow @EricPFierce

> FDA may impose more QA checks on heparin makers. Story

> Recipharm snags $114 million loan, says its shopping. Article

> Heart attack test alert from Alere. More

> FDA takes aim at Spanish drugmaker. Item

CRO News

 @NesaNFierce: What should a CDMO do with 90 million Euros? Buy more CDMOs, as Recipharm announced it will do. Article | Follow @NesaNFierce

> SGS picks up testing company Vitrology for an undisclosed fee. News

> Pfizer's David Simmons joins PPD as new CEO and chairman. Story

> PRA expands European ops with new Dutch and British offices. More

> Quintiles survey shows U.S. and U.K. payers want to improve R&D with increased involvement. Item

Vaccines News

> Wishing you a happy HIV Vaccine Awareness Day. Report

> Vitamin D boosts TB shot as cancer therapy. Article

> DNA vaccine swats TB and HIV. News

> HIV vaccine carries its own adjuvant into clinical trials. Story

And Finally... A new study indicates that certain "obesity genes" may influence the foods that are chosen by people who are overweight. More

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.